BCRB 2018

19/09/2018

ARCON for cT2-4 larynx carcinoma

Randomization

Accelerated Radiotherapy + CarbOgen and Nicotinamide

Accelerated Radiotherapy

Fractionation schedule:

primary

metastatic nodes

Acc. RT ARCON

68 Gy

68 Gy 68 Gy

64 Gy*

*Aim: improve tumor control with equal toxicity between arms!

39

Janssens et al., J Clin Oncol 2012

ARCON for cT2-4 larynx carcinoma

345 patients

78% AR 79% ARCON

86% AR 93% ARCON

Janssens et al., J Clin Oncol 2012

40